ALECNIB 150 MG (ALECTINIB)

ALECNIB 150 MG (ALECTINIB)

Compare

Description

Alecnib, Alectinib

Alecnib is an anti-cancer targeted chemotherapy drug used for the treatment of cancer. Alecnib is a tyrosine kinase inhibitor (TKI). Tyrosine Kinase are specific enzymes which signal cancer cells to grow, thus Alecnib works to block these signals that are being sent out by Tyrosine kinase enzymes to stop the growth of cancer cells.

Generic Name Alectinib
Brand Name Alecnib
Packing 56
Manufacturer Everest Pharmaceuticals Ltd.
Form Capsule
Strength 150mg
Country Bangladesh

Uses
Alecnib is an anti cancer targeted therapy drug which is used in chemotherapy. Alecnib is known as a tyrosine kinase inhibitor or ALK.
How it Works
Alecnib is a tyrosine kinase inhibitor (TKI). Tyrosine Kinase are specific enzymes which signal cancer cells to grow, thus Alecnib works to block these signals that are being sent out by Tyrosine kinase enzymes to stop the growth of cancer cells.
Common Side effects
Some of the common side effects that can occur with consumption of this medication are

Anemia (low red blood cell count)
Fatigue (including weakness)
Constipation
Low blood calcium (hypocalcemia)
Swelling (edema)
Low potassium (hypokalemia)
Muscle and bone pain
Increased creatinine level
Increased liver function tests: AST, ALT, bilirubin (liver problems)
High blood glucose (Hyperglycemia)
Low blood sodium (hyponatremia)
Nausea
Decreased lymphocyte count (white blood cells that fight infection)
Low blood phosphate (hypophosphatemia)

Expert advice
Before starting alectinib treatment, make sure you tell your doctor about any other medications you are taking

Storage
Store Alecnib in a cold dry area away from Sunlight exposure.

Other Notes
This product is certified and registered with Directorate General of Drug Administration (DGDA) , Ministry of Health & Family Welfare, Government of the People’s republic of Bangladesh.

Reviews

There are no reviews yet.

Be the first to review “ALECNIB 150 MG (ALECTINIB)”

Your email address will not be published. Required fields are marked *

X